A Phase 4 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 2 sites in Japan. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-01.
Sponsored by BioNTech SE · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 41st largest by enrollment, is one of 5 that started in 2020, is one of 11 in phase 4, and was the 4th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 28th largest by enrollment, is one of 10 that started in 2020, is one of 2 in phase 4, and was the 7th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults.
The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19:
From protocol amendment 3, this study is transitioned from a clinical trial to a postmarketing study (Phase 4) according to the Japanese regulation, because BNT162b2 was approved by the Ministry of Health, Labour and Welfare on 14 February 2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BNT162b2 (intramuscular injection)
Biological: BNT162b2
Placebo (intramuscular injection)
Other: Placebo
BNT162b2 (intramuscular injection)
Placebo (intramuscular injection)
Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1
Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\>=)37.5 to 38.4 degrees(deg) Celsius(C), \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2
Systemic events were recorded by participants in an e-diary. Fever was categorized as \>= 37.5 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Dose 1 up to 1 month after Dose 2
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.
Time frame: Dose 1 up to 12 months after Dose 2
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category
The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\<)0.8\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*upper limit of normal (ULN); platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.
Time frame: Within 1 day after Dose 1
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category
The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category
The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).
Time frame: Within 7 days after Dose 2
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category
Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
Time frame: From baseline (observation prior to Dose 1) up to 1 day after Dose 1
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category
Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
Time frame: From baseline (observation prior to Dose 1) up to 7 days after Dose 1
Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category
Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
Time frame: Before Dose 2 up to 7 days after Dose 2
Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2
GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.
Time frame: 1 month after Dose 2
Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.
Time frame: Before vaccination up to 1 month after Dose 2
GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2
GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.
Time frame: NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2
GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.
Time frame: NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2
GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2
GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.
Time frame: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2
GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).
Time frame: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2
| Milestone | BNT162b2 | Placebo | Placebo Then BNT162b2 |
|---|---|---|---|
| Started | 119 | 41 | 0 |
| Completed | 119 | 41 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | BNT162b2 | Placebo | Placebo Then BNT162b2 |
|---|---|---|---|
| Started | 119 | 6 | 35 |
| Completed | 117 | 3 | 35 |
| Not completed | 2 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Other | 2 | 2 | 0 |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Redness: Mild | 7.6 (3.5 to 13.9) | 0.0 (0.0 to 8.6) |
| Redness: Moderate | 5.9 (2.4 to 11.7) | 0.0 (0.0 to 8.6) |
| Redness: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Redness: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Swelling: Mild | 9.2 (4.7 to 15.9) | 0.0 (0.0 to 8.6) |
| Swelling: Moderate | 3.4 (0.9 to 8.4) | 0.0 (0.0 to 8.6) |
| Swelling: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Swelling: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Mild | 57.1 (47.7 to 66.2) | 2.4 (0.1 to 12.9) |
| Pain at the injection site: Moderate | 27.7 (19.9 to 36.7) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Severe | 1.7 (0.2 to 5.9) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, severe: \>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Redness: Mild | 6.0 (2.5 to 12.0) | 0.0 (0.0 to 8.6) |
| Redness: Moderate | 4.3 (1.4 to 9.8) | 0.0 (0.0 to 8.6) |
| Redness: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Redness: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Swelling: Mild | 4.3 (1.4 to 9.8) | 0.0 (0.0 to 8.6) |
| Swelling: Moderate | 4.3 (1.4 to 9.8) | 0.0 (0.0 to 8.6) |
| Swelling: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Swelling: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Mild | 50.9 (41.4 to 60.3) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Moderate | 26.7 (18.9 to 35.7) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Severe | 1.7 (0.2 to 6.1) | 0.0 (0.0 to 8.6) |
| Pain at the injection site: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\>=)37.5 to 38.4 degrees(deg) Celsius(C), \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Fever: >= 37.5 to 38.4 deg C | 11.8 (6.6 to 19.0) | 0.0 (0.0 to 8.6) |
| Fever: >38.4 to 38.9 deg C | 2.5 (0.5 to 7.2) | 0.0 (0.0 to 8.6) |
| Fever: >38.9 to 40.0 deg C | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Fever: >40.0 deg C | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Fatigue: Mild | 22.7 (15.5 to 31.3) | 7.3 (1.5 to 19.9) |
| Fatigue: Moderate | 16.8 (10.6 to 24.8) | 2.4 (0.1 to 12.9) |
| Fatigue: Severe | 0.8 (0.0 to 4.6) | 0.0 (0.0 to 8.6) |
| Fatigue: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Headache: Mild | 21.8 (14.8 to 30.4) | 7.3 (1.5 to 19.9) |
| Headache: Moderate | 10.1 (5.3 to 17.0) | 7.3 (1.5 to 19.9) |
| Headache: Severe | 0.8 (0.0 to 4.6) | 0.0 (0.0 to 8.6) |
| Headache: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Chills: Mild | 16.0 (9.9 to 23.8) | 4.9 (0.6 to 16.5) |
| Chills: Moderate | 8.4 (4.1 to 14.9) | 0.0 (0.0 to 8.6) |
| Chills: Severe | 0.8 (0.0 to 4.6) | 0.0 (0.0 to 8.6) |
| Chills: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Mild | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Moderate | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Diarrhea: Mild | 3.4 (0.9 to 8.4) | 0.0 (0.0 to 8.6) |
| Diarrhea: Moderate | 1.7 (0.2 to 5.9) | 0.0 (0.0 to 8.6) |
| Diarrhea: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Diarrhea: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Mild | 10.1 (5.3 to 17.0) | 2.4 (0.1 to 12.9) |
| New or worsened muscle pain: Moderate | 4.2 (1.4 to 9.5) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Mild | 9.2 (4.7 to 15.9) | 4.9 (0.6 to 16.5) |
| New or worsened joint pain: Moderate | 4.2 (1.4 to 9.5) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Severe | 0.8 (0.0 to 4.6) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
Systemic events were recorded by participants in an e-diary. Fever was categorized as \>= 37.5 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither "no" nor missing for at least 1 day.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Fever: >= 37.5 to 38.4 deg C | 25.0 (17.4 to 33.9) | 0.0 (0.0 to 8.6) |
| Fever: >38.4 to 38.9 deg C | 6.9 (3.0 to 13.1) | 0.0 (0.0 to 8.6) |
| Fever: >38.9 to 40.0 deg C | 0.9 (0.0 to 4.7) | 0.0 (0.0 to 8.6) |
| Fever: >40.0 deg C | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Fatigue: Mild | 25.9 (18.2 to 34.8) | 2.4 (0.1 to 12.9) |
| Fatigue: Moderate | 31.0 (22.8 to 40.3) | 0.0 (0.0 to 8.6) |
| Fatigue: Severe | 3.4 (0.9 to 8.6) | 0.0 (0.0 to 8.6) |
| Fatigue: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Headache: Mild | 25.0 (17.4 to 33.9) | 7.3 (1.5 to 19.9) |
| Headache: Moderate | 17.2 (10.9 to 25.4) | 4.9 (0.6 to 16.5) |
| Headache: Severe | 1.7 (0.2 to 6.1) | 0.0 (0.0 to 8.6) |
| Headache: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Chills: Mild | 24.1 (16.7 to 33.0) | 2.4 (0.1 to 12.9) |
| Chills: Moderate | 19.8 (13.0 to 28.3) | 0.0 (0.0 to 8.6) |
| Chills: Severe | 1.7 (0.2 to 6.1) | 0.0 (0.0 to 8.6) |
| Chills: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Mild | 0.9 (0.0 to 4.7) | 0.0 (0.0 to 8.6) |
| Vomiting: Moderate | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Vomiting: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Diarrhea: Mild | 5.2 (1.9 to 10.9) | 0.0 (0.0 to 8.6) |
| Diarrhea: Moderate | 0.0 (0.0 to 3.1) | 2.4 (0.1 to 12.9) |
| Diarrhea: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| Diarrhea: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Mild | 9.5 (4.8 to 16.3) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Moderate | 6.9 (3.0 to 13.1) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Severe | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened muscle pain: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Mild | 12.9 (7.4 to 20.4) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Moderate | 11.2 (6.1 to 18.4) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Severe | 0.9 (0.0 to 4.7) | 0.0 (0.0 to 8.6) |
| New or worsened joint pain: Grade 4 | 0.0 (0.0 to 3.1) | 0.0 (0.0 to 8.6) |
An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2 | 10.9 (5.9 to 18.0) | 7.3 (1.5 to 19.9) |
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2 | 1.7 (0.2 to 5.9) | 0 (0.0 to 8.6) |
The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\<)0.8\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*upper limit of normal (ULN); platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| 20-64 Years: Monocytes | 11.1 | 0.0 |
| 65-85 Years: Lymphocytes | 22.2 | 0.0 |
| 65-85 Years: Monocytes | 11.1 | 0.0 |
| 65-85 Years: Creatinine | 11.1 | 0.0 |
The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| 20-64 Years: Eosinophils | 11.1 | 0.0 |
| 65-85 Years: Lymphocytes | 0.0 | 33.3 |
The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \<0.8\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \<0.9\*LLN and \>1.1\*ULN; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes, neutrophils \<0.8\*LLN and \>1.2\*ULN; basophils, eosinophils, monocytes \>1.2\*ULN; bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN; urea nitrogen, creatinine \>1.3\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category | 22.2 | 33.3 |
Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| 20-64 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline) | 22.2 | 0.0 |
| 20-64 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline) | 55.6 | 0.0 |
| 20-64 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 33.3 |
| 65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline) | 33.3 | 0.0 |
| 65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline) | 22.2 | 0.0 |
| 65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 2 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Urea Nitrogen: Normal (at baseline) to Grade 1 (at post baseline) | 0.0 | 33.3 |
| 65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline) | 33.3 | 0.0 |
Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| 20-64 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 20-64 Years- Neutrophil Decrease: Grade 1 (at baseline) to Normal (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline) | 11.1 | 33.3 |
| 65-85 Years- Hemoglobin: Grade 1 (at baseline) to Grade 2 (at post baseline) | 11.1 | 0.0 |
| 65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline) | 0.0 | 33.3 |
| 65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline) | 0.0 | 33.3 |
Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.
| Percentage of participants | BNT162b2 | Placebo |
|---|---|---|
| 20-64 Years- Alanine Aminotransferase Increased: Grade 1 (before dose 2) to Normal (post dose 2) | 11.1 | 0.0 |
| 20-64 Years- Eosinophils: Grade 1 (before dose 2) to Normal (post dose 2) | 11.1 | 0.0 |
| 20-64 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2) | 11.1 | 0.0 |
| 20-64 Years- Hemoglobin: Grade 1 (before dose 2) to Normal (post dose 2) | 11.1 | 33.3 |
| 20-64 Years- Neutrophil Decrease: Grade 1 (before dose 2) to Normal (post dose 2) | 22.2 | 0.0 |
| 20-64 Years- WBC Decrease: Grade 1 (before dose 2) to Normal (post dose 2) | 11.1 | 0.0 |
| 65-85 Years-Aspartate Aminotransferase Increased: Normal (before dose 2) to Grade 1 (post dose 2) | 11.1 | 0.0 |
| 65-85 Years- Bilirubin: Grade 1 (before dose 2) to Normal (post dose 2) | 11.1 | 0.0 |
| 65-85 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2) | 11.1 | 0.0 |
| 65-85 Years- Hemoglobin: Grade 1 (before dose 2) to Grade 2 (post dose 2) | 11.1 | 0.0 |
| 65-85 Years- Lymphocytes: Normal (before dose 2) to Grade 1 (post dose 2) | 0.0 | 33.3 |
| 65-85 Years- Neutrophil Decrease: Normal (before dose 2) to Grade 1 (post dose 2) | 22.2 | 33.3 |
| 65-85 Years- Urea Nitrogen: Normal (before dose 2) to Grade 1 (post dose 2) | 0.0 | 33.3 |
| 65-85 Years- WBC Decrease: Normal (before dose 2) to Grade 1 (post dose 2) | 11.1 | 33.3 |
GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.
| Titer | BNT162b2 | Placebo |
|---|---|---|
| Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2 | 524.5 (459.7 to 598.4) | 10.6 (9.8 to 11.4) |
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.
| Fold rise | BNT162b2 | Placebo |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2 | 51.5 (45.2 to 58.7) | 1.1 (1.0 to 1.1) |
GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.
| Titer | BNT162b2 | Placebo |
|---|---|---|
| NT50: Baseline | 10.2 (9.8 to 10.6) | 10.0 (10.0 to 10.0) |
| NT50: 21 days after Dose 1 | 29.2 (24.3 to 35.2) | 10.0 (10.0 to 10.0) |
| NT50: 7 days after Dose 2 | 408.2 (352.0 to 473.3) | 10.0 (10.0 to 10.0) |
| NT50: 14 days after Dose 2 | 379.4 (335.3 to 429.3) | 10.0 (10.0 to 10.0) |
| NT50: 6 months after Dose 2 | 145.6 (126.1 to 168.2) | 20.5 (20.5 to 20.5) |
| NT50: 12 months after Dose 2 | 74.2 (59.6 to 92.3) | 63.8 (0.5 to 8440.7) |
| NT90: Baseline | 10.1 (9.9 to 10.2) | 10.0 (10.0 to 10.0) |
| NT90: 21 days after Dose 1 | 11.4 (10.5 to 12.5) | 10.0 (10.0 to 10.0) |
| NT90: 7 days after Dose 2 | 104.3 (90.1 to 120.7) | 10.0 (10.0 to 10.0) |
| NT90: 14 days after Dose 2 | 95.8 (84.8 to 108.2) | 10.0 (10.0 to 10.0) |
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.
| Fold rise | BNT162b2 | Placebo |
|---|---|---|
| NT50: before vaccination up to 21 days after Dose 1 | 2.9 (2.4 to 3.4) | 1.0 (1.0 to 1.0) |
| NT50: before vaccination up to 7 days after Dose 2 | 40.1 (34.6 to 46.5) | 1.0 (1.0 to 1.0) |
| NT50: before vaccination up to 14 days after Dose 2 | 37.2 (32.9 to 42.1) | 1.0 (1.0 to 1.0) |
| NT50: before vaccination up to 6 months after Dose 2 | 14.3 (12.4 to 16.5) | 2.1 (2.1 to 2.1) |
| NT50: before vaccination up to 12 months after Dose 2 | 7.3 (5.9 to 9.1) | 6.4 (0.0 to 844.1) |
| NT90: before vaccination up to 21 days after Dose 1 | 1.1 (1.1 to 1.2) | 1.0 (1.0 to 1.0) |
| NT90: before vaccination up to 7 days after Dose 2 | 10.3 (8.9 to 12.0) | 1.0 (1.0 to 1.0) |
| NT90: before vaccination up to 14 days after Dose 2 | 9.5 (8.4 to 10.7) | 1.0 (1.0 to 1.0) |
GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.
No measurements were reported for this outcome.
GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).
No measurements were reported for this outcome.
Collected over Local reactions/systemic events: within 7 days after each dose; SAEs: from Dose 1 up to 12 months after Dose 2 except for Placebo Then BNT162b2 reporting arm; SAEs for Placebo Then BNT162b2 reporting arm: from Dose 3 up to 6 months after Dose 4: other AEs: from Dose 1 up to 1 month after Dose 2 for BNT162b2 and Placebo arms; from Dose 3 up to 1 month after Dose 4 for Placebo Then BNT162b2 reporting arm.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BNT162b2 | 0/119 (0%) | 2/119 (1.7%) | 111/119 (93.3%) |
| Placebo | 0/41 (0%) | 0/41 (0%) | 12/41 (29.3%) |
| Placebo Then BNT162b2 | 0/35 (0%) | 0/35 (0%) | 31/35 (88.6%) |
| Event | BNT162b2 | Placebo | Placebo Then BNT162b2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/119 | 0/41 | 0/35 |
| Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/119 | 0/41 | 0/35 |
| Event | BNT162b2 | Placebo | Placebo Then BNT162b2 |
|---|---|---|---|
| Injection site pain (PAIN)General disorders | 109/119 | 1/41 | 0/35 |
| Injection site painGeneral disorders | 0/119 | 0/41 | 31/35 |
| Fatigue (FATIGUE)General disorders | 75/119 | 4/41 | 0/35 |
| FatigueGeneral disorders | 0/119 | 0/41 | 21/35 |
| Headache (HEADACHE)Nervous system disorders | 64/119 | 8/41 | 0/35 |
| Chills (CHILLS)General disorders | 58/119 | 3/41 | 0/35 |
| HeadacheNervous system disorders | 2/119 | 1/41 | 17/35 |
| PyrexiaGeneral disorders | 1/119 | 1/41 | 16/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/119 | 0/41 | 13/35 |
| Pyrexia (FEVER)General disorders | 43/119 | 0/41 | 0/35 |
Safety population included all randomized participants who received at least 1 dose of the study intervention.
| Age, Continuous(Years) | BNT162b2 | Placebo | Total |
|---|---|---|---|
| Mean | 46.8 ± 16.16 | 44.8 ± 17.76 | 46.3 ± 16.55 |
| Age, Customized(Participants) | BNT162b2 | Placebo | Total |
|---|---|---|---|
| 20-64 Years | 97 | 33 | 130 |
| 65-85 Years | 22 | 8 | 30 |
| Sex: Female, Male(Participants) | BNT162b2 | Placebo | Total |
|---|---|---|---|
| Female | 60 | 19 | 79 |
| Male | 59 | 22 | 81 |
| Ethnicity (NIH/OMB)(Participants) | BNT162b2 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 119 | 41 | 160 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BNT162b2 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 119 | 41 | 160 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Nov 2021, 13 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
Of 44 industry-sponsored phase 4 interventional studies under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 13 months is above that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine